Literature DB >> 9783782

Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes.

S Roayaie1, J V Guarrera, M Q Ye, S N Thung, S Emre, T M Fishbein, S R Guy, P A Sheiner, C M Miller, M E Schwartz.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer and constitutes 10% of primary liver malignancies. Surgery is the optimal therapy; the majority of the patients will require extensive resections that are associated with significant morbidity.
METHODS: We retrospectively studied the records of 26 patients who underwent exploratory laparotomy for intrahepatic cholangiocarcinoma between June 1991 and December 1997 at the Mount Sinai Hospital. Patients with perihilar (Klatskin) tumors were excluded. All patients were considered resectable based on CT or MRI findings. Patients with positive margins or nodal invasion received adjuvant chemotherapy and radiation.
RESULTS: Sixteen patients underwent 18 resections; in 10 patients the tumors were unresectable at laparotomy and only biopsy was performed. The mean age (62 versus 53 years) was significantly higher, and the mean total bilirubin level (0.71 versus 6.17 mg/dL) was significantly lower in the resected group (p=0.031 and 0.017, respectively). No patient with a total bilirubin over 1.2 mg/dL was found to be resectable. Median actuarial survivals were 42.9+/-8.9 months for resectable and 6.7+/-3.6 months for unresectable patients (p=0.005). Positive margins were associated with significantly shorter disease-free survival. But resected patients with positive margins survived significantly longer than those who were unresectable. Tumor size, presence of satellite nodules, and degree of tumor necrosis on histologic examination were significant predictors of outcomes. Survival among patients receiving adjuvant therapy was not significantly altered.
CONCLUSIONS: We conclude that an aggressive surgical approach is warranted in patients with ICC because resection offers the only hope for longterm survival. Our findings emphasize the importance of achieving tumor-free margins. Noncurative resection offers a survival advantage over no resection. Histologic examination of resected specimens can help select patients with poor prognoses.

Entities:  

Mesh:

Year:  1998        PMID: 9783782     DOI: 10.1016/s1072-7515(98)00203-8

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  31 in total

1.  Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.

Authors:  Yuji Morine; Mitsuo Shimada; Tohru Utsunomiya; Satoru Imura; Tetsuya Ikemoto; Jun Hanaka; Mami Kanamoto; Nobuhiro Kurita; Hidenori Miyake
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

2.  [Radiological diagnosis of Klatskin's tumour].

Authors:  S Pauls; M S Juchems; H-J Brambs
Journal:  Radiologe       Date:  2005-11       Impact factor: 0.635

3.  Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study.

Authors:  Xianwu Luo; Lei Yuan; Yi Wang; Ruiliang Ge; Yanfu Sun; Gongtian Wei
Journal:  J Gastrointest Surg       Date:  2014-01-07       Impact factor: 3.452

4.  Comparison of the prognostic accuracy of the sixth and seventh editions of the TNM classification for intrahepatic cholangiocarcinoma.

Authors:  Dario Ribero; Gennaro Nuzzo; Marco Amisano; Mariano Tomatis; Alfredo Guglielmi; Stefano Maria Giulini; Luca Aldrighetti; Fulvio Calise; Giorgio Enrico Gerunda; Antonio Daniele Pinna; Lorenzo Capussotti
Journal:  HPB (Oxford)       Date:  2011-02-09       Impact factor: 3.647

Review 5.  The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics.

Authors:  Yuji Morine; Mitsuo Shimada
Journal:  J Gastroenterol       Date:  2015-04-02       Impact factor: 7.527

6.  Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma.

Authors:  Yeona Cho; Tae Hyung Kim; Jinsil Seong
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

7.  Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery.

Authors:  Shiro Miwa; Shinichi Miyagawa; Akira Kobayashi; Yasuhiko Akahane; Takenari Nakata; Motohiro Mihara; Kei Kusama; Junpei Soeda; Shinichiro Ogawa
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

8.  [Surgical therapy of intrahepatic cholangiocellular carcinoma].

Authors:  H Lang; G C Sotiropoulos; E Brokalaki; N R Frühauf; J Radü; A Paul; J Wohlschlaeger; H A Baba; M Malagó; C E Broelsch
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

9.  The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium.

Authors:  A C Okaro; A R Deery; R R Hutchins; B R Davidson
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

10.  Long-Term Survival of Recurrent Intrahepatic Cholangiocarcinoma: The Impact and Selection of Repeat Surgery.

Authors:  Tomoaki Yoh; Etsuro Hatano; Satoru Seo; Yukihiro Okuda; Hiroaki Fuji; Yoshinobu Ikeno; Kojiro Taura; Kentaro Yasuchika; Hideaki Okajima; Toshimi Kaido; Shinji Uemoto
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.